Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement ...

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...

Germany's Merck is on the verge of a billion-euro takeover of US biopharmaceutical company Springworks Therapeutics, with the ...

Germany’s Merck KGaA (DE:MRK) is in advanced talks to buy U.S.-based SpringWorks Therapeutics (SWTX) for roughly $3.5 billion, aiming to boost ...

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...

BofA is moving to No Rating on SpringWorks Therapeutics (SWTX) given that shares are trading near the Merck KGaA (MKGAY) potential offer price ...

Washington and Beijing increasingly look likely to de-escalate their trade war. But the economic damage and ongoing ...

Scores of FDA employees are searching for an exit from an agency in turmoil, especially staffers tasked with reviewing drug ...

The article highlights various financial dynamics within the pharmaceutical industry amid prevailing economic conditions.